Aldeyra Therapeutics, Inc. (ALDX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and metabolic diseases. The company's primary late-stage product candidates are reproxalap (for dry eye disease and allergic conjunctivitis) and ADX-2191 (for retinitis pigmentosa). The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(16.85) million | $(8.99) million | $(24.93) million | $(24.60) million |
| Loss Per Share (Basic/Diluted) | $(0.28) | $(0.15) | $(0.42) | $(0.42) |
| Research & Development Expenses | $14.97 million | $6.96 million | $21.15 million | $18.20 million |
| General & Administrative Expenses | $3.04 million | $3.38 million | $6.25 million | $8.95 million |
| Cash, Cash Equivalents & Marketable Securities | $120.33 million (as of June 30, 2024) | |||
| Debt (Current Portion) | $15.24 million (Hercules Credit Facility) | |||
| Stockholders' Equity | $98.31 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by approximately $8.0 million in Q2 2024 compared to Q2 2023, driven by higher external clinical development costs and drug product manufacturing costs.
- Decreased G&A Spend: General and administrative expenses decreased by $0.4 million in Q2 2024, primarily due to lower personnel costs, consulting expenditures, and legal fees.
- Cash Position: Total cash, cash equivalents, and marketable securities decreased from $142.8 million at year-end 2023 to $120.3 million at June 30, 2024. This reflects a net cash outflow of $71.8 million for the six months ended June 30, 2024, largely due to operating losses and net purchases of marketable securities ($48.6 million used in investing activities).
- Debt Status: The company has $15.0 million outstanding under its Hercules Credit Facility. The Fourth Loan Tranche commitment of $20.0 million expired unutilized on May 1, 2024. No additional amounts are available for borrowing.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities are sufficient to fund projected operating expenses and debt obligations for at least the next 12 months (through mid-2025) and potentially through 2026, excluding potential licensing revenue. However, the company will require additional funding in the future to complete development and commercialization.
- AbbVie Option Agreement: The company holds an exclusive option agreement with AbbVie Inc. regarding reproxalap. AbbVie paid $6.0 million in non-refundable fees ($1.0 million option payment + $5.0 million extension fee), recorded as deferred revenue. The option expires 18 months after the agreement date (April 2025) or 10 business days after FDA approval of reproxalap, whichever is earlier. As of August 1, 2024, the option has not been exercised.
- Regulatory Status:
- Reproxalap: Received a Complete Response Letter (CRL) from the FDA in November 2023 regarding its NDA for dry eye disease. The FDA required an additional adequate and well-controlled study. The company has submitted a Special Protocol Assessment (SPA) for a new trial design.
- ADX-2191: Received a CRL in June 2023 for primary vitreoretinal lymphoma. In Q1 2024, the company deprioritized ADX-2191 for proliferative vitreoretinopathy and primary vitreoretinal lymphoma due to FDA requirements for clinical trials deemed not feasible.
- Legal Proceedings: A putative securities class action lawsuit (Juliana Paice v. Aldeyra Therapeutics, Inc.) is pending, alleging false statements regarding the NDA prospects for ADX-2191 and reproxalap. A related derivative complaint was voluntarily dismissed in June 2024.
- Management Transition: Bruce Greenberg, Senior Vice President of Finance and Interim CFO, announced his departure effective August 31, 2024. The company plans to outsource principal financial and accounting officer roles.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $120.3 million cash balance against the burn rate of ~$25 million per six months, considering the need for additional funding before 2026.
- Debt Maturity: Confirm the repayment schedule for the $15.0 million Hercules term loan, which matures on October 1, 2024, and the company's ability to refinance or repay without triggering a default.
- AbbVie Option Exercise: Monitor the status of the AbbVie option, which could provide up to $100 million in upfront cash plus milestones if exercised, or result in the company retaining full commercial responsibility if it expires.
- Reproxalap Trial Design: Assess the progress and FDA feedback on the new clinical trial design intended to address the deficiencies noted in the November 2023 CRL.
- Legal Exposure: Track the outcome of the pending securities class action lawsuit regarding the NDA prospects of reproxalap and ADX-2191.